CogniXense for Rare Disease Drug Discovery Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome.

In 2021, Unravel Biosciences licensed CogniXense to identify and create drugs to treat central nervous system disorders like Rett syndrome. This year, they received approval for their first human clinical trial to test a disease-modifying drug for Rett syndrome. #RettSyndromeAwarenessMonth

October marks #RettSyndromeAwarenessMonth, a time to shine a light on Rett syndrome.

At ProQR, we are proud to partner with the Rett Syndrome Research Trust developing #Axiomer #RNAEditing oligonucleotides to target genetic variants that cause Rett syndrome.

Excited to join the 37th National Rett Syndrome Days by @afsr.bsky.social in Paris, Oct 11–12. I’ll discuss about “Regulation of MECP2 Transport & Expression: Innovative Paths for Rett Syndrome". More info at jnsr.afsr.fr #RettSyndrome #Research #RettSyndromeAwarenessMonth

#Rett #sydrome is rare and affects 1 out of 10,000 children.
#Rettsyndromeawareness
#Rettsyndromeawarenessmonth
#Rettsyndrome

💜 October is Rett Syndrome Awareness Month

🗓️ Oct 8: Hear from experts on emerging therapies, managing key symptoms, and team based strategies to improve patient centered care.

🔗 Register 👉 bit.ly/4816OHv

#RettSyndromeAwarenessMonth #RettSyndrome #CME